Yellow Fever Vaccination of a Primary Vaccinee During Adalimumab Therapy

J Travel Med. 2015 Jul-Aug;22(4):279-81. doi: 10.1111/jtm.12209. Epub 2015 Apr 29.

Abstract

In this case report, we describe a 63-year-old female with Crohn's disease since age 16 years, and on adalimumab therapy, who inadvertently received a yellow fever vaccine (YFV) 4 days before her next dose of adalimumab. She had never received YFV. Her next dose of tumor necrosis factor (TNF) antagonist was held. She did not report any adverse effects referable to the vaccine. Reverse transcriptase-polymerase chain reaction (RT-PCR) for yellow fever (YF) viral RNA on days 12 and 18 postvaccination was negative. Neutralizing antibody to YF virus vaccine was immunoprotective on day 18 following vaccination, which further increased by day 26. A neutralizing antibody obtained 2 years following vaccination also remained immunoprotective.

Publication types

  • Case Reports

MeSH terms

  • Adalimumab* / administration & dosage
  • Adalimumab* / adverse effects
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / adverse effects
  • Antibodies, Viral / blood
  • Crohn Disease* / drug therapy
  • Crohn Disease* / immunology
  • Drug Monitoring / methods
  • Female
  • Humans
  • Immunity / drug effects*
  • Immunologic Tests / methods
  • Middle Aged
  • Travel*
  • Treatment Outcome
  • Vaccination / methods
  • Yellow Fever / prevention & control*
  • Yellow Fever Vaccine / administration & dosage
  • Yellow Fever Vaccine / adverse effects
  • Yellow fever virus / immunology*

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Viral
  • Yellow Fever Vaccine
  • Adalimumab